Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.

Clin Cancer Res 2014 Jun 2;20(11):2984-93. Epub 2014 Apr 2.

Authors' Affiliations: Departments of Biomedical Imaging and Image-guided Therapy, Internal Medicine I, Internal Medicine III, and Opthalmology and Optometry, and Institute of Pathology, Medical University of Vienna, Vienna, Austria.

Purpose: To determine the value of diffusion-weighted MRI (DWI-MRI) for pretherapeutic imaging of fluorodeoxyglucose (FDG)-avid lymphoma and lymphoma with variable FDG avidity.

Experimental Design: Treatment-naïve patients with lymphoma who were referred for whole-body staging were included in this prospective study. Group A included patients with FDG-avid lymphoma (e.g., Hodgkin, diffuse large B-cell, and follicular lymphoma), whereas Group B included patients with lymphoma of variable FDG avidity [e.g., extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)]. All patients underwent DWI-MRI and 18F-FDG- positron emission tomography/computed tomography (PET/CT). Region-based sensitivity and agreement with Ann Arbor staging, relative to the reference standard, were calculated for DWI-MRI, and, in Group B, also 18F-FDG-PET/CT and contrast-enhanced (CE-) CT.

Results: In Group A (100 patients), DWI-MRI had a region-based sensitivity of 97%, and with regard to staging, agreed with the reference standard in 94 of 100 patients (κ, 0.92). In Group B (40 patients; 38 MALT lymphomas and 2 small lymphocytic lymphomas/chronic lymphocytic leukemias), DWI-MRI, 18F-FDG-PET/CT, and CE-CT had region-based sensitivities of 94.4%, 60.9%, and 70.7%, respectively. With regard to staging in Group B, DWI-MRI, 18F-FDG-PET/CT, and CE-CT agreed with the reference standard in 37 of 40, 26 of 40, and 24 of 40 patients, with κ values of 0.89, 0.52, and 0.43, respectively.

Conclusions: In patients with FDG-avid lymphoma, DWI-MRI seems to be only slightly inferior to 18F-FDG-PET/CT with regard to pretherapeutic regional assessment and staging. In patients with lymphoma subtypes that show a variable FDG avidity (e.g., MALT lymphoma), DWI-MRI seems to be superior to both 18F-FDG-PET/CT and CE-CT.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-3355DOI Listing
June 2014
25 Reads

Publication Analysis

Top Keywords

fdg-avid lymphoma
12
variable fdg
12
18f-fdg-pet/ct ce-ct
12
reference standard
12
patients lymphoma
12
patients
11
lymphoma
11
100 patients
8
agreed reference
8
region-based sensitivity
8
dwi-mri
8
lymphoma variable
8
group included
8
included patients
8
fdg avidity
8
patients fdg-avid
8
regard staging
8
diffusion-weighted mri
8
dwi-mri 18f-fdg-pet/ct
8
assessment staging
8

Similar Publications